Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used for type 2 diabetes and obesity management, yet their effects on thyroid function tests remain inadequately characterized. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.